Fibrinogen and coronary risk

Current Cardiology Reports

Volumn 1, Issue 2, 1999, Pages 112-118

  Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; FIBRINOGEN; PLASMINOGEN;

BLOOD; CORONARY ARTERY DISEASE; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; PHYSIOLOGY; REVIEW; RISK FACTOR; SEX DIFFERENCE;

BIOLOGICAL MARKERS; CORONARY DISEASE; CYTOKINES; FEMALE; FIBRINOGEN; HUMANS; MALE; PLASMINOGEN; RISK FACTORS; SEX FACTORS;

EID: 0033156533     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0068-y     Document Type: Article

References (68)

1. Braunwald E: Shattuck Lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360-1369.
2. Ross R: Arteriosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
3. Danesh J, Collins R, Appleby P, et al.: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. J Am Med Assoc 1998, 279:1477-1482.
4. Ernst E, Koenig W: Fibrinogen and cardiovascular risk. Vascular Medicine 1997, 2:115-125.
5. Caen J P, Dravet L, Montalescot, G: Abstracts Presented to the Fourth International Fibrinogen Symposium. Fibrinogen & Cardiovascular Disease. Blood Coagul Fibrinolysis 1999, (suppl 1):S91-S121.
6. Woodward M, Lowe GDO, Rumley A, et al.: Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J 1998, 19:55-62.
7. Smith FB, Lee AJ, Fowkes FRG, et al.: Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997, 17:3321-3325.
8. Smith FB, Rumley A, Lee AJ, et al.: Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998, 100:758-763.
9. Koch M, Kutkuhn B, Grabensee B, et al.: Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997, 12:2603-2611.
10. Sweetnam PM, Thomas HF, Yarnell JWG, et al.: Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. The Caerphilly and Speedwell Studies. Eur Heart J 1996, 17:1814-1820.
11. Koenig W, Sund M, Filipiak B, et al.: Plasma viscosity and the risk of coronary heart disease. Results from the MONICA-Augsburg Cohort Study 1984-1992. Arterioscler Thromb Vasc Biol 1998, 18:768-772.
12. Jose J, Selvakumar D, Selvakumar R, et al.: Plasma fibrinogen - an independent risk factor for ischaemic heart disease. Indian Heart J 1998, 50:45-48.
13. Markovitz JH, Kulkarni K, Goldschmidt-Clermont P, et al.: Increased platelet activation and fibrinogen in Asian Indians. Eur Heart J 1998, 19:720-726.
14. Folsom AR, Pankow JS, Williams RR, et al.: Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb Haemost 1998, 2:400-404.
15. Rosenson RS: Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993, 22:933-940.
16. Lowe GDO: The impact of fibrinogen on arterial disease. Excerpta Medica 1993.
17. Eichner JE, Moore WE, McKee PA, et al.: Fibrinogen levels in women having coronary angiography. Am J Cardiol 1996, 78:15-18.
18. Tribouilloy Ch, Peltier M, Colas L, et al.: Fibrinogen is an independent marker for thoracic aortic artherosclerosis. Am J Cardiol 1998, 81: 321-326.
19. Danielsen R, Önundarson PT, Thors H, et al.: Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. Scand Cardiovasc J 1998, 32:87-95.
20. Kruskal JB, Commerford PJ, Franks JJ et al.: Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987, 317:1361-1365.
21. Becker RC, Cannon ChP, Bovill EG, et al.: Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial). Am J Cardiol 1996, 78:142-147.
22. Toss H, Lindahl B, Siegbahn A, et al.: Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997, 96:4204-4210.
23. Verheggen PWHM, de Maat MPM, Manger Cats V, et al.: Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J 1999 [in press].
24. Humphries SE: Genetic regulation of fibrinogen. Eur Heart J 1995, 16 (suppl A):15-20.
25. Carter AM, Mansfield MW, Stickland MH, et al.: β-Fibrinogen gene - 455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM-Diabetes Care 1996, 19:1265-1268.
26. Humphries SE, Henry JA, Montgomery HE: Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coag Fibrinolysis 1999, (suppl 1):S17-S21.
27. Zito F, Di Castelnuovo A, Amore C, et al.: Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol 1997, 17:3489-3494.
28. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries S, et al.: A common mutation (G-455-A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997, 99:3034-3039.
29. Montgomery HE, Clarkson P, Nwose OM, et al.: The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453 - A polymorphism of the beta-fibrinogen gene. Arterioscler Thromb Vasc Biol 1996, 16:386-391.
30. Margaglione M, Cappucci G, Colaizzo D, et al.: Fibrinogen plasma level in an apparently healthy general populationrelation to environmental and genetic determinants. Thromb Haemost 1998, 80:805-810.
31. Folsom AR.: Fibrinogen and cardiovascular risk markers. Blood Coagul Fibrinol 1999, 10(suppl 1):S13-S16.
32. Scarabin P-Y, Aillaud M-F, Amouyel P, et al.: Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The Prime Study. Thromb Haemost 1998, 80:749-756.
33. Folsom AR, Peacock JM, Nieto FJ, et al.: Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens 1998, 16:1579-1583.
34. Junker R, Heinrich J, Schulte H, et al.: Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Munster study. J Hypertens 1998, 16:917-923.
35. Welty FK, Mittleman MA, Wilson PWF, et al.: Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham Offspring Population. Circulation 1997, 95:825-830.
36. Danesh J, Peto R: Risk factors for coronary heart disease and infection with Helicobcter pylori: meta-analysis of 18 studies. Br Med J 1998, 316:1130-1132.
37. Regnstrom J, Jofinge S, Bavenholm P, et al.: Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease. J Intern Med 1998, 243:109-113.
38. Koenig W, Rothenbacher D, Hoffmeister A, et al.: Infection with Helicobacter pylori is not a major independent risk factor for coronary heart disease: Lack of a role of CagA-positive strains and absence of a systemic inflammatory response. Circulation in press.
39. Toss H, Gnarpe J, Gnarpe H, et al.: Increased fibrinogen levels are associated with persistent Chlamydia penumoniae infection in unstable coronary artery disease. Eur Heart J 1998, 19:570-577.
40. Hoffmeister A, Rothenbacher D, Wanner P, et al.: Systemic inflammation, seropositivity to chlamydial lipopolysaccharide and coronary artery disease - a case-control study. Circulation in press.
41. Torgano G, Cosentini R, Mandelli C, et al.: Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma levels in patients with ischemic heart disease. Circulation 1999, 99:1555-1559.
42. Anderson JL, Muhlestein JB, Carlquist J, et al.: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 1999, 99:1540-1547.
43. Hicks RCJ, Golledge J, Mir-Hasseine R, et al. Vasoactive effects of fibrinogen on saphenous vein. Nature 1996, 379:818-820.
44. Retzinger GS, DeAnglis AP, Patuto SJ.: Adsorption of fibrinogen to droplets of liquid hydrophobic phases. Functionality of the bound protein and biological implications. Arterioscler Thromb Vasc Biol 1998, 18:1948-1957.
45. Rabbani LE, Loscalzo J: Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994, 105: 1-7.
46. Schneider DJ, Taatjes DJ, Howards DB, et al.: Increased reactivity of platelets induced by fibrinogen independent of ist bindings to the IIb-IIIa surface glycoprotein;: A potential contributor to cardiovascular risk. J Am Coll Cardiol 1999, 33:261-266.
47. Fatah K, Hamsten A, Blombäck B, et al.: Fibrin gel network characteristics and coronary heart disease: Relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992, 68:130-135.
48. Scrutton MC, Ross-Murphy SB, Bennett GM, et al.: Changes in clot deformability - a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinol 1994, 4:719-723.
49. McDonagh J, Lee MH: How does hyperfibrinogenemia lead to thrombosis? Fibrinolysis & Proteolysis 1997, 11(suppl 1):13-17.
50. Koenig W, Ernst E: The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992, 94(2-3):93-107.
51. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 96:874-877.
52. Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease. Is there a link? Lancet 1997, 350:430-436.
53. Folsom AR, Wu KK, Rosamond WD, et al.: Prospective Study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997, 96:1102-1108.
54. Koenig W, Ernst E: Exercise and thrombosis. Coronary Artery Disease 1999 [in press].
55. Koenig W, Hoffmeister A, Hombach V: Hyperfibrinogenemia and cardiovascular risk: possible strategies for intervention. Fibrinolysis & Proteolysis 1997, (suppl 1): 41-46.
56. Kockx M, Gervois PP, Poulain P, et al.: Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor - a. Blood. 1999 33:2291-2298
57. Staels B, Koenig W, Habib A, et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators. Nature 1998 393:790-793.
58. Palazon CP, Alfon J, Gaffney P, et al.: Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk. Atherosclerosis 1998, 136:333-345.
59. Behar S for the BIP Study Group: Lowering fibrinogen levels: clinical update. Blood Coagul Fibrinol 1999, 10(suppl 1):S41-S43.
60. Prisco D, Paniccia R, Bandinelli B, et al.: Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. Int J Clin Lab Res 1998, 28:170-173.
61. The Writing Group for the Estradiol Clotting Factors Study: Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996, 75:476-480.
62. Fröhlich M, Schunkert H, Hense HW, et al.: Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br J Haematol 1998, 100:577-581.
63. Lip GYH, Blann AD, Jones A F, et al.: Effects of hormonereplacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis. Am Heart J 1997, 134:764-771.
64. Walsh BW, Kuller LH, Wild RA, et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998, 279:1445-1451.
65. Giri S, Thompson PD, Taxel P, et al.: Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 1998, 137:359-366.
66. O'Keefe JH, Kim SC, Hall RR, et al.: Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997, 29:1-5.
67. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998, 280:605-613.
68. Rosenson RS, Tangney CC, Hafner JM: Intra-individual variability of fibrinogen levels and cardiovascular profile. Arterioscler Thromb 1994, 14:1928-1932.